According to Bristol-Myers Squibb's latest financial reports the company has $12.28 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $12.28 B | 32.71% |
2022-12-31 | $9.25 B | -46.27% |
2021-12-31 | $17.22 B | 4.69% |
2020-12-31 | $16.45 B | 6.87% |
2019-12-31 | $15.39 B | 75.74% |
2018-12-31 | $8.75 B | 28.58% |
2017-12-31 | $6.81 B | 7.28% |
2016-12-31 | $6.35 B | 48.71% |
2015-12-31 | $4.27 B | -42.57% |
2014-12-31 | $7.43 B | 64.31% |
2013-12-31 | $4.52 B | 59.95% |
2012-12-31 | $2.82 B | -67.61% |
2011-12-31 | $8.73 B | 19.61% |
2010-12-31 | $7.30 B | -14.25% |
2009-12-31 | $8.51 B | 3.01% |
2008-12-31 | $8.26 B | 271.46% |
2007-12-31 | $2.22 B | -44.56% |
2006-12-31 | $4.01 B | -30.8% |
2005-12-31 | $5.79 B | -22.41% |
2004-12-31 | $7.47 B | 34.38% |
2003-12-31 | $5.56 B | 39.43% |
2002-12-31 | $3.98 B | -29.45% |
2001-12-31 | $5.65 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 86.70% | ๐บ๐ธ USA |
Novartis NVS | $13.96 B | 13.70% | ๐จ๐ญ Switzerland |
Pfizer PFE | $12.69 B | 3.34% | ๐บ๐ธ USA |
AbbVie ABBV | $12.81 B | 4.36% | ๐บ๐ธ USA |
Eli Lilly LLY | $2.92 B | -76.16% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | -10.88% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | -19.15% | ๐ซ๐ท France |
Biogen BIIB | $1.04 B | -91.45% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | -42.24% | ๐บ๐ธ USA |
AstraZeneca AZN | $5.86 B | -52.28% | ๐ฌ๐ง UK |